Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Definitive antifungal therapy is typically based on Candida species and clinical status, rather than susceptibility reports. Antifungal susceptibility testing is available, but the impact on treatment decisions is unknown. The purpose of this study was to assess antifungal therapy in hospitalized patients with candidaemia during the time period between the start of empirical therapy and after antifungal susceptibility testing reports are available. METHODS: A retrospective study of 161 hospitalized patients with candidaemia was conducted. Patients who received fluconazole or an echinocandin were evaluated for changes in empirical antifungal therapy prior to and after susceptibility reporting. RESULTS: One hundred and sixty-one patients aged 59 ± 16 years (male, 54%; Caucasian, 52%; APACHE II score ≥ 15, 48%; and intensive care unit, 50%) were identified, of whom 130 (81%) had fluconazole-susceptible candidaemia. Fifty-eight patients (36%) were initiated on fluconazole and 103 (64%) on an echinocandin. The mean time from culture to the susceptibility report was 5 ± 2 days. Prior to availability of the susceptibility report, 20 fluconazole-initiated patients (34%) were switched to an echinocandin, while 14 echinocandin-initiated patients (14%) were switched to fluconazole. Once a susceptibility report was available, 35 of 89 (39%) patients with fluconazole-susceptible candidaemia on an echinocandin were de-escalated to fluconazole. Eleven patients on fluconazole just prior to a susceptibility report were identified with a fluconazole-resistant Candida species. CONCLUSIONS: Using antifungal susceptibility testing, patients given fluconazole with fluconazole-resistant Candida species were identified. Less than 40% of echinocandin-treated patients with fluconazole-susceptible organisms were de-escalated to fluconazole. Antifungal susceptibility testing may help to identify patients in need of clinical intervention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AFST results, if available, may also be used to guide step-down treatment decisions and identify instances where treatment may be ineffective [17].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [17]
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
Self-citationZaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 387
Pai, M. P., Turpin, R. S., & Garey, K. W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-06 · Cited by 159
Self-citationThe role of antifungal susceptibility testing in the therapy of candidiasis
Hospenthal, D. R., Murray, C. K., & Rinaldi, M. G. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.10.003 · Cited by 109
Current Status and Future Perspectives on Molecular and Serological Methods in Diagnostic Mycology
Lau, A. F., Chen, W., Sleiman, S., & Sorrell, T. C. (2009) · Future Microbiology · doi:10.2217/fmb.09.70 · Cited by 78
Garey, K. W., Pai, M. P., Suda, K. J., Turpin, R. S., Rege, M. D., Mingo, D. E., & Bearden, D. T. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1365 · Cited by 64
Self-citationRole of antifungal susceptibility testing in patient management
Forrest, G. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328010682c · Cited by 39
Baddley, J. W., Patel, M., Jones, M., Cloud, G. A., Smith, A. C., & Moser, S. A. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.06.004 · Cited by 31
Hadley, S. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.2.415 · Cited by 29
Comparison of Risk Factors for Candidemia Versus Bacteremia in Hospitalized Patients
Amrutkar, P., Rege, M., Chen, H., LaRocco, M., Gentry, L. O., & Garey, K. W. (2006) · Infection · doi:10.1007/s15010-006-5677-4 · Cited by 25
Self-citation
Cited by
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region
Tan, T. Y., Hsu, L. Y., Alejandria, M. M., Chaiwarith, R., Chinniah, T., Chayakulkeeree, M., Choudhury, S., Chen, Y. H., Shin, J. H., Kiratisin, P., et al. (2016) · Medical Mycology · doi:10.1093/mmy/myv114 · Cited by 139
The current treatment landscape: Candidiasis
Bassetti, M., Peghin, M., & Timsit, J.-F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw392 · Cited by 99
Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab512 · Cited by 20
Vallabhaneni, S., Sapiano, M., Weiner, L. M., Lockhart, S. R., & Magill, S. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx175 · Cited by 14
Metadata
- Authors
- Shah, D. N., Yau, R., Weston, J., Lasco, T. M., Salazar, M., Palmer, H. R., & Garey, K. W.
- Affiliations
- Baylor St. Luke's Medical Center (US)
- Corresponding author
- Garey, K. W.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-23
- Volume
- 66
- Issue
- 9
- Pages
- 2146-2151
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2109074575
- Cited by
- 75
- References
- 15
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 10 · 2015: 10 · 2014: 8 · 2013: 11 · 2012: 4
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- candidemia, antifungal susceptibility testing, fluconazole, echinocandins, empirical antifungal therapy, fluconazole resistance, Candida species, antimicrobial stewardship, hospitalized patients
- MeSH terms
- Caspofungin, Aged, Antifungal Agents, Candida, Drug Utilization, Female, Humans, Intensive Care Units, Length of Stay, Male, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Risk Factors, Fluconazole, APACHE, Echinocandins, Lipopeptides, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.